These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31769316)

  • 1. Methoxyphenol derivatives as reversible inhibitors of myeloperoxidase as potential antiatherosclerotic agents.
    Jayaraj P; Narasimhulu CA; Maiseyeu A; Durairaj R; Rao S; Rajagopalan S; Parthasarathy S; Desikan R
    Future Med Chem; 2020 Jan; 12(2):95-110. PubMed ID: 31769316
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthetic Guaiacol Derivatives as Promising Myeloperoxidase Inhibitors Targeting Atherosclerotic Cardiovascular Disease.
    Premkumar J; Sampath P; Sanjay R; Chandrakala A; Rajagopal D
    ChemMedChem; 2020 Jul; 15(13):1187-1199. PubMed ID: 32368837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
    Aldib I; Gelbcke M; Soubhye J; Prévost M; Furtmüller PG; Obinger C; Elfving B; Alard IC; Roos G; Delporte C; Berger G; Dufour D; Zouaoui Boudjeltia K; Nève J; Dufrasne F; Van Antwerpen P
    Eur J Med Chem; 2016 Nov; 123():746-762. PubMed ID: 27537923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of myeloperoxidase-catalyzed tyrosylation by phenolic antioxidants in vitro.
    Kato Y; Nagao A; Terao J; Osawa T
    Biosci Biotechnol Biochem; 2003 May; 67(5):1136-9. PubMed ID: 12834295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
    Shaw SA; Vokits BP; Dilger AK; Viet A; Clark CG; Abell LM; Locke GA; Duke G; Kopcho LM; Dongre A; Gao J; Krishnakumar A; Jusuf S; Khan J; Spronk SA; Basso MD; Zhao L; Cantor GH; Onorato JM; Wexler RR; Duclos F; Kick EK
    Bioorg Med Chem; 2020 Nov; 28(22):115723. PubMed ID: 33007547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors.
    Cui MY; Xiao MW; Xu LJ; Chen Y; Liu AL; Ye J; Hu AX
    Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900174. PubMed ID: 31657061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations.
    Ramírez-Durán LA; Rosales-Hernández MC; Hernández-Rodríguez M; Mendieta-Wejebe JE; Trujillo-Ferrara J; Correa-Basurto J
    Curr Pharm Des; 2013; 19(12):2204-15. PubMed ID: 23016839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of chemical features of potent myeloperoxidase inhibitors.
    Soubhye J; Meyer F; Furtmüller P; Obinger C; Dufrasne F; Antwerpen PV
    Future Med Chem; 2016 Jul; 8(11):1163-77. PubMed ID: 27402298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L. (Zygophyllaceae).
    Bensalem S; Soubhye J; Aldib I; Bournine L; Nguyen AT; Vanhaeverbeek M; Rousseau A; Boudjeltia KZ; Sarakbi A; Kauffmann JM; Nève J; Prévost M; Stévigny C; Maiza-Benabdesselam F; Bedjou F; Van Antwerpen P; Duez P
    J Ethnopharmacol; 2014 Jun; 154(2):361-9. PubMed ID: 24746482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coumaric acid derivatives as tyrosinase inhibitors: Efficacy studies through in silico, in vitro and ex vivo approaches.
    Varela MT; Ferrarini M; Mercaldi VG; Sufi BDS; Padovani G; Nazato LIS; Fernandes JPS
    Bioorg Chem; 2020 Oct; 103():104108. PubMed ID: 32750608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification.
    Van Antwerpen P; Prévost M; Zouaoui-Boudjeltia K; Babar S; Legssyer I; Moreau P; Moguilevsky N; Vanhaeverbeek M; Ducobu J; Nève J; Dufrasne F
    Bioorg Med Chem; 2008 Feb; 16(4):1702-20. PubMed ID: 18063373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
    Soubhye J; Chikh Alard I; Aldib I; Prévost M; Gelbcke M; De Carvalho A; Furtmüller PG; Obinger C; Flemmig J; Tadrent S; Meyer F; Rousseau A; Nève J; Mathieu V; Zouaoui Boudjeltia K; Dufrasne F; Van Antwerpen P
    J Med Chem; 2017 Aug; 60(15):6563-6586. PubMed ID: 28671460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors.
    Soubhye J; Aldib I; Elfving B; Gelbcke M; Furtmüller PG; Podrecca M; Conotte R; Colet JM; Rousseau A; Reye F; Sarakbi A; Vanhaeverbeek M; Kauffmann JM; Obinger C; Nève J; Prévost M; Zouaoui Boudjeltia K; Dufrasne F; Van Antwerpen P
    J Med Chem; 2013 May; 56(10):3943-58. PubMed ID: 23581551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO).
    Hu CH; Neissel Valente MW; Halpern OS; Jusuf S; Khan JA; Locke GA; Duke GJ; Liu X; Duclos FJ; Wexler RR; Kick EK; Smallheer JM
    Bioorg Med Chem Lett; 2021 Jun; 42():128010. PubMed ID: 33811992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HOCl traps with myeloperoxidase inhibitors in prevention of low density lipoprotein oxidation.
    Jerlich A; Fritz G; Kharrazi H; Hammel M; Tschabuschnig S; Glatter O; Schaur RJ
    Biochim Biophys Acta; 2000 Aug; 1481(1):109-18. PubMed ID: 11004581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4'-Aminochalcones as novel inhibitors of the chlorinating activity of myeloperoxidase.
    Zeraik ML; Ximenes VF; Regasini LO; Dutra LA; Silva DH; Fonseca LM; Coelho D; Machado SA; Bolzani VS
    Curr Med Chem; 2012; 19(31):5405-13. PubMed ID: 22963624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.
    Forbes LV; Sjögren T; Auchère F; Jenkins DW; Thong B; Laughton D; Hemsley P; Pairaudeau G; Turner R; Eriksson H; Unitt JF; Kettle AJ
    J Biol Chem; 2013 Dec; 288(51):36636-47. PubMed ID: 24194519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Series of Ferulic Acid Amides Reveals Unexpected Peroxiredoxin 1 Inhibitory Activity with in vivo Antidiabetic and Hypolipidemic Effects.
    Yasmin S; Cerchia C; Badavath VN; Laghezza A; Dal Piaz F; Mondal SK; Atlı Ö; Baysal M; Vadivelan S; Shankar S; Siddique MUM; Pattnaik AK; Singh RP; Loiodice F; Jayaprakash V; Lavecchia A
    ChemMedChem; 2021 Feb; 16(3):484-498. PubMed ID: 33030290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins.
    Malle E; Marsche G; Panzenboeck U; Sattler W
    Arch Biochem Biophys; 2006 Jan; 445(2):245-55. PubMed ID: 16171772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of myeloperoxidase inhibitors.
    Galijasevic S
    Bioorg Med Chem Lett; 2019 Jan; 29(1):1-7. PubMed ID: 30466896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.